The present disclosure relates to a stable multiparticulate composition comprising coated discrete units of an amine drug or a pharmaceutically acceptable salt thereof, with stabilizing amount of one or more nitrite quencher. The composition provides effective control of the level of nitrosamine drug substance-related impurities (NDSRIs) in the drug product during shelf life of the product.
The disclosure relates to methods of treating nail psoriasis in a subject comprising administering a therapeutically effective amount of an anti-IL-23p19 antibody hum13B8-b to the subject. The disclosure also relates to methods of improving one or more of total- modified Nail Psoriasis Severity Index (mNAPSI), Scale to Evaluate Nail Psoriasis severity (ViSENPsO) score, total Nail Psoriasis Severity Index (NAPSI), nail pain numeric rating scale (NRS) score, Modified Nail Psoriasis Severity Index (mNAPSI), Nail Psoriasis Severity Index (NAPSI), Visual medical scale to evaluate nail psoriasis severity (ViSENPsO), or nail pain numeric rating scale (NRS) score in a subject with nail psoriasis by administering a therapeutically effective amount of an anti-IL-23p19 antibody hum13B8-b to the subject. The disclosure further relates to methods of increasing Quality of Life (QoL) in a subject with nail psoriasis by administering a therapeutically effective amount of an anti-IL-23p19 antibody hum13B8-b to the subject. The disclosure further relates to pharmaceutical compositions of an anti-IL-23p19 antibody hum13B8-b for the treatment of nail psoriasis in subject. The disclosure further relates to the use of an anti-IL-23p19 antibody hum13B8-b for the manufacture of a medicament for treating nail psoriasis in a subject.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
7.
METHOD OF REDUCING NITROSAMINE LEVELS IN PHARMACEUTICAL PRODUCTS AND IMPROVED FORMULATIONS THEREOF
The present invention provides a pharmaceutical formulation comprising an amine-containing pharmaceutically active agent, wherein said composition comprises one or more components selected from a low DMA containing active agent, a nitrite scavenger and/or a pH modifier/buffer. The use of the pH modifier/buffer in the formulation provides a pH in the range of about pH 2 to about pH 10. The disclosure also provides a packaged pharmaceutical formulation comprising an amine-containing pharmaceutically active agent, wherein said packaging i) comprises an oxygen absorbent and/or ii) is breathable or vented to allow diffusion of N-Nitrosamine, such as NDMA, out of the packaging.
The disclosure relates to methods of producing recombinant proteins. More specifically, the disclosure relates to methods of manufacturing biologics, such as monoclonal antibodies, fusion proteins, or antigen-binding fragments thereof. In particular, the disclosure relates to methods and use of feed regimens that improve the cell viability and target protein productivity and lower host cell protein impurities of such manufacturing processes. More specifically, the disclosure relates to methods of producing Tildrakizumab.
C07K 16/06 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies from serum
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
9.
COMBINATION THERAPY COMPRISING AN ANTI-IL-23 ANTIBODY AND A CORTICOSTEROID FOR TREATING PSORIASIS
The present disclosure relates to a combination of the anti-IL-23 antibody tildrakizumab in combination with a corticosteroid for use in the treatment of plaque psoriasis.
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 39/00 - Medicinal preparations containing antigens or antibodies
SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (India)
SUN PHARMACEUTICAL INDUSTRIES LIMITED (India)
Inventor
Chidrewar, Gajanan
Mandhane, Sanjay
Ramanathan, Vikram Krishna
Abstract
The disclosure relates to methods of treating autoimmune disorders or reducing or suppressing the symptoms of a chronic inflammatory disorder of the digestive tract using an inhibitor of the interleukin-23 signaling pathway and a modulator of the sphingosine-1- phosphate signaling pathway. The disclosure also relates to pharmaceutical compositions comprising an inhibitor of the interleukin-23 pathway and a modulator of the sphingosine-1- phosphate signaling pathway. The disclosure further relates to combinations of an inhibitor of the interleukin-23 signaling pathway and a modulator of the sphingosine-1-phosphate signaling pathway for use in the treatment of autoimmune disorders. The disclosure further relates to pharmaceutical kits comprising an inhibitor of the interleukin-23 signaling pathway, a modulator of the sphingosine-1-phosphate signaling pathway, and instructions for use. The disclosure further relates to the use of a combination of an inhibitor of the interleukin-23 signaling pathway and a modulator of the sphingosine-1-phosphate signaling pathway for the manufacture of a medicament for treating an autoimmune disorder.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
The present invention relates to an aqueous composition of cholecalciferol. The present invention relates to an oil-free, stable, aqueous composition of cholecalciferol at a concentration ranging from 400 IU-600000 IU. The invention also includes process of preparing such compositions and use of such compositions for the treatment and prevention of vitamin D deficiency.
16 - Paper, cardboard and goods made from these materials
35 - Advertising and business services
36 - Financial, insurance and real estate services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Manuals; newsletters; pamphlets and brochures; pharmaceutical information leaflets; quick reference pocket guides (1) Administration of prescription drug programs designed to process medical insurance claims for products used by consumers; business administration of a patient support program for facilitating access to pharmaceutical products; business administration of a patient support program for facilitating the distribution of pharmaceutical products; business administration of a patient support program for facilitating the reimbursement of pharmaceutical product; consulting services in the field of patient relationship management for healthcare providers; patient relationship management services
(2) Charitable services, namely, providing financial support to disadvantaged patients for the purpose of facilitating good health; providing financial support to patients for the purchase of medications
(3) Advisory and consultancy services for patients in the field of patient access to medical treatment services; charitable services, namely, patient assistance program to provide drugs free of charge to low-income patients without prescription drug coverage; information, advisory and consultancy services in the field of medical testing services; medical nursing services; providing information relating to the preparation and dispensing of medications
16 - Paper, cardboard and goods made from these materials
35 - Advertising and business services
36 - Financial, insurance and real estate services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Manuals; newsletters; pamphlets and brochures; pharmaceutical information leaflets; quick reference pocket guides (1) Administration of prescription drug programs designed to process medical insurance claims for products used by consumers; business administration of a patient support program for facilitating access to pharmaceutical products; business administration of a patient support program for facilitating the distribution of pharmaceutical products; business administration of a patient support program for facilitating the reimbursement of pharmaceutical product; consulting services in the field of patient relationship management for healthcare providers; patient relationship management services
(2) Charitable services, namely, providing financial support to disadvantaged patients for the purpose of facilitating good health; providing financial support to patients for the purchase of medications
(3) Advisory and consultancy services for patients in the field of patient access to medical treatment services; charitable services, namely, patient assistance program to provide drugs free of charge to low-income patients without prescription drug coverage; information, advisory and consultancy services in the field of medical testing services; medical nursing services; providing information relating to the preparation and dispensing of medications
15.
PROCESS FOR THE PREPARATION OF TIRZEPATIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
The present invention relates to tirzepatide or a pharmaceutically acceptable salt thereof. The present invention also relates to a process for the preparation of tirzepatide or pharmaceutically acceptable salt thereof. The present invention also relates to novel fragments as intermediates and use thereof in the preparation of tirzepatide.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
16.
CYCLOSPORINE FORMULATIONS FOR USE IN PATIENTS UNDERGOING CATARACT SURGERY
A method of preparing patients for cataract surgery includes topical administration of a cyclosporine solution. The administration may occur twice daily and may occur over the course of 28 days. The method results in an improved error prediction for 1-month spherical equivalent refractive outcome and improved ocular surface irregularity.
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Providing online information regarding patient experiences with plaque psoriasis treatments, namely, featuring supportive personal stories on the subjects of health, emotional impact of plaque psoriasis, and treatment
The present invention relates to long acting glucagon-like peptide-1 and human glucose- dependent insulinotropic polypeptide (GIP) agonist polypeptides which may be useful for treating type 2 diabetes mellitus (T2D), diabetes with obesity, obesity and hyperlipidemia.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
The disclosure relates to methods of using GLP-1 analog and composition thereof for the treatment of metabolic disorders, such as obesity, diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH) and hypertriglyceridemia. More specifically, the disclosure relates to methods for treating obesity in a subject, comprising administering a therapeutically effective amount of GL0034 to the subject. The disclosure also relates to methods for treating a metabolic disorder in a subject in need thereof, comprising administering a therapeutically effective amount of GL0034 to the subject. The disclosure further relates to compositions comprising GL0034 for the treatment of obesity, diabetes or other metabolic disorder in a subject.
A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A stable nanomicellar ophthalmic solution comprising cyclosporine and a method of preparing the nanomicellar solution. The present invention further relates to a stable nanomicellar solution comprising a cyclosporine form with characteristic XRD peaks at 2-theta (deg.) 6.9, 7.8, 9.4 and 15.9 or amorphous cyclosporine. The present invention also relates to use of this stable nanomicellar ophthalmic solution in the treatment of dry eye.
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
21.
METHOD OF INJECTING DIHYDROERGOTAMINE INTO THE BODY
A method is provided for the acute treatment of migraine headaches with or without aura by injecting dihydroergotamine mesylate into a subject. The method includes storing the dihydroergotamine mesylate in an autoinjector at room temperature in a foil pouch. The method further includes removing the autoinjector from the pouch; removing a cap of the autoinjector; pushing the autoinjector down against an injection site of the subject to depress a safety guard; pressing and releasing an activation button on the autoinjector to start injection; and holding the autoinjector against the injection site for at least 10 seconds irrespective of whether a click is generated. The method further includes confirming that the injection is complete by viewing a change of color in a viewing window of the autoinjector, and lifting the autoinjector up away from the injection site and allowing the guard to drop down and lock over a needle.
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
22.
GLP-1/GIP DUAL, GLP-1/GCG DUAL AND GLP-1/GIP/GCG TRIPLE RECEPTOR AGONISTS
The present invention relates to GLP-1/GIP/GCG triple receptor agonists and use thereof in the treatment or prevention of Type 2 diabetes mellitus (T2DM), hyperlipidemia/dyslipidemia, metabolic syndromes, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), neurodegenerative disorders, fibrosis, cardiovascular risks, and/or obesity.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A perfusion container for directly administering to patients a dose of an antineoplastic drug calculated according to a patient's parameter, wherein the first perfusion container comprises a solution of antineoplastic drug at a concentration and volume such that the amount of antineoplastic drug in the container is equal to the calculated dose for one patient but less than the calculated dose for a second patient, the calculated dose is provided to first patient within 5% variance by directly administering the full volume of the solution of antineoplastic drug from the first perfusion container, further the first perfusion container is accompanied by a second top-up perfusion container comprising a solution of antineoplastic drug at a concentration and volume such that the calculated dose is provided within 5% variance by directly administering the full volume of the solution of antineoplastic drug from the first perfusion container and the second top-up container to the second patient.
The present disclosure provides GLP-1/GIP and GLP-1/GCG dual receptor agonists comprising incretin analog polypeptides and use thereof in the treatment or prevention of Type 2 diabetes mellitus (T2DM), hyperlipidemia/dyslipidemia, metabolic syndromes, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction- associated steatohepatitis (MASH), neurodegenerative disorders, fibrosis, cardiovascular risks, and/or obesity.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention relates to long acting glucagon-like peptide-1 and human glucose-dependent insulinotropic polypeptide (GIP) dual agonist polypeptide which may be useful for treating type 2 diabetes mellitus (T2D), diabetes with obesity, obesity and hyperlipidemia.
The present invention relates to a stable nanomicellar ophthalmic formulation comprising cyclosporine, hydrogenated 40 polyoxyl castor oil, octoxynol-40, and an aqueous vehicle, wherein the stable nanomicellar ophthalmic formulation is made by a method comprising: a) mixing the hydrogenated 40 polyoxyl castor oil and the octoxynol-40, wherein the mixing produces a Mixture A comprising a water content of less than 3%; b) adding the cyclosporine to the Mixture A to form a Mixture B; and c) mixing the Mixture B with the aqueous vehicle, thereby forming the stable nanomicellar ophthalmic formulation.
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
27.
METHODS AND COMPOSITIONS FOR TREATING PLAQUE PSORIASIS
This disclosure relates to methods of treating plaque psoriasis comprising administering an anti-IL-23p19 antibody hum13B8-b to a patient in need thereof. This disclosure also relates to pharmaceutical compositions of an anti-IL-23p19 antibody hum13B8-b or antigen binding fragment thereof for the treatment plaque psoriasis in a patient. This disclosure further relates to the use of an anti-IL-23p19 antibody hum13B8-b or antigen binding fragment thereof for the manufacture of a medicament for treating plaque psoriasis in a patient. In some embodiments, the disclosure relates to methods, pharmaceutical compositions, and medicaments for treating plaque psoriasis wherein treatment results in the patient maintaining a Physician's Global Assessment (PGA) score of "clear" or "almost clear" with at least a 2- point reduction from Baseline, or results in the patient maintaining at least a 50% reduction in the Psoriasis Area and Severity Index (PASI 50), or results in the patient maintaining at least a 75% reduction in the Psoriasis Area and Severity Index (PASI 75), or results in the patient maintaining at least a 90% reduction in the Psoriasis Area and Severity Index (PASI 90), or results in the patient maintaining a 100% reduction in the Psoriasis Area and Severity Index (PASI 100) for at least up to about 60 weeks to at least up to about 432 weeks. In some embodiments, the disclosure relates to methods, pharmaceutical compositions, and medicaments for treating plaque psoriasis wherein treatment results in the patient experiencing no increase in adverse events (AEs), drug-related AEs, severe adverse events (SAEs), Tier 1 AEs, or Tier 2 AEs for at least up to about 60 weeks to at least up to about 432 weeks.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
This disclosure relates to methods of treating plaque psoriasis comprising administering an anti-IL-23p19 antibody hum13B8-b to a patient in need thereof. This disclosure also relates to pharmaceutical compositions of an anti-IL-23p19 antibody hum13B8-b or antigen binding fragment thereof for the treatment plaque psoriasis in a patient. This disclosure further relates to the use of an anti-IL-23p19 antibody hum13B8-b or antigen binding fragment thereof for the manufacture of a medicament for treating plaque psoriasis in a patient. In some embodiments, the disclosure relates to methods, pharmaceutical compositions, and medicaments for treating plaque psoriasis wherein treatment results in the patient maintaining a Physician's Global Assessment (PGA) score of “clear” or “almost clear” with at least a 2-point reduction from Baseline, or results in the patient maintaining at least a 50% reduction in the Psoriasis Area and Severity Index (PASI 50), or results in the patient maintaining at least a 75% reduction in the Psoriasis Area and Severity Index (PASI 75), or results in the patient maintaining at least a 90% reduction in the Psoriasis Area and Severity Index (PASI 90), or results in the patient maintaining a 100% reduction in the Psoriasis Area and Severity Index (PASI 100) for at least up to about 60 weeks to at least up to about 432 weeks. In some embodiments, the disclosure relates to methods, pharmaceutical compositions, and medicaments for treating plaque psoriasis wherein treatment results in the patient experiencing no increase in adverse events (AEs), drug-related AEs, severe adverse events (SAEs), Tier 1 AEs, or Tier 2 AEs for at least up to about 60 weeks to at least up to about 432 weeks.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 39/00 - Medicinal preparations containing antigens or antibodies
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system; Pharmaceutical preparations for the treatment of immune system related diseases and disorders and immunologically mediated inflammatory disorders; Pharmaceutical preparations for the treatment of cancer
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system; Pharmaceutical preparations for the treatment of immune system related diseases and disorders and immunologically mediated inflammatory disorders; Pharmaceutical preparations for the treatment of cancer
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system; Pharmaceutical preparations for the treatment of immune system related diseases and disorders and immunologically mediated inflammatory disorders; Pharmaceutical preparations for the treatment of cancer
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system; Pharmaceutical preparations for the treatment of immune system related diseases and disorders and immunologically mediated inflammatory disorders; Pharmaceutical preparations for the treatment of cancer
The disclosure provides compositions and systems for topical ophthalmic application, which include an aqueous mixture of bromfenac and flowable mucoadhesive polymer, for treating inflammation and inflammatory conditions of the eye.
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system; Pharmaceutical preparations for the treatment of immune system related diseases and disorders and immunologically mediated inflammatory disorders; Pharmaceutical preparations for the treatment of cancer
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system; Pharmaceutical preparations for the treatment of immune system related diseases and disorders and immunologically mediated inflammatory disorders; Pharmaceutical preparations for the treatment of cancer
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system; Pharmaceutical preparations for the treatment of immune system related diseases and disorders and immunologically mediated inflammatory disorders; Pharmaceutical preparations for the treatment of cancer
The present invention relates to a method of treating acne comprising administering to the subject, a pharmaceutical composition comprising micronized isotretinoin; wherein, the composition is administered once daily to the subject under a fasting state, at a dose of about 0.4 mg/kg to about 1.6 mg/kg of isotretinoin. In particular, the composition further comprises one or more surfactants; and one or more co-solvents.
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1)(7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.
Provided herein include formulations for topical administration, such as ophthalmic formulations, and methods of using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and/or a polyalkoxylated alcohol and may include nanomicelles. Also include methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 9/00 - Medicinal preparations characterised by special physical form
A stable nanomicellar ophthalmic solution comprising cyclosporine and a method of preparing the nanomicellar solution. The present invention further relates to the stable nanomicellar solution comprising cyclosporine form with characteristic XRD peaks at 2-theta (deg.) 6.9, 7.8, 9.4 and 15.9 or amorphous cyclosporine. The present invention also relates to use of this stable nanomicellar L ophthalmic solution in dry eye.
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
The present disclosure relates to a stable pharmaceutical composition comprising a Histamine H2-receptor antagonist or a pharmaceutically acceptable salt thereof and a stabilizing amount of at least one alkalizer. The composition provides effective control of the level of nitrosamine drug substance-related impurities (NDSRIs) such as NDMA in the drug product during shelf life of the product.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for use in the treatment of diseases and disorders of the central nervous system; pharmaceutical preparations for the treatment of mental disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for use in the treatment of diseases and disorders of the central nervous system; pharmaceutical preparations for the treatment of mental disorders
The invention relates to stable compositions of an antibody against human programmed death receptor PD-1, or antigen binding fragments thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. The present invention relates to pharmaceutical compositions of an anti-PD1 antibody comprising a buffer, a sugar or sugar alcohol and a surfactant. In some embodiments of the invention, the formulations may be administered to a subject by intravenous or subcutaneous administration.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the prevention of breast cancer in post-menopausal women; Pharmaceutical preparations for the prevention of bone and skeletal diseases
45 - Legal and security services; personal services for individuals.
Goods & Services
Providing online information regarding patient experiences with plaque psoriasis treatments, namely, featuring supportive personal stories on the subjects of health, emotional impact of plaque psoriasis, and treatment
52.
TOPICAL CYCLOSPORINE-CONTAINING FORMULATIONS AND USES THEREOF
Provided herein are formulations for topical ophthalmic formulations containing 0.087-0.093 wt % of cyclosporine, and methods of making and using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and/or a polyalkoxylated alcohol and may include nanomicelles. Also included herein are methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.
The present disclosure relates to a stable multiparticulate composition comprising coated discrete units of an amine drug or a pharmaceutically acceptable salt thereof, with stabilizing amount of one or more nitrite quencher. The composition provides effective control of the level of nitrosamine drug substance-related impurities (NDSRIs) in the drug product during shelf life of the product.
The present invention relates to an intravenous infusion dosage form comprising: an aqueous solution of pemetrexed or its pharmaceutically acceptable salt at a concentration ranging from 1.0 mg/ml to 20.0 mg/ml present in a multilayered flexible plastic infusion container, wherein the multilayered flexible plastic infusion container has an oxygen scavenger layer sandwiched between an outermost and an innermost layer of the container, the container being free of a polyimide and wherein the multilayered flexible plastic infusion container filled with the aqueous solution of pemetrexed is autoclavable.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
B32B 27/08 - Layered products essentially comprising synthetic resin as the main or only constituent of a layer next to another layer of a specific substance of synthetic resin of a different kind
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the prevention of breast cancer in post-menopausal women; Pharmaceutical preparations for the prevention of bone and skeletal diseases
The present invention provides a ready to use stable aqueous dosage form of norepinephrine comprising an aqueous solution of norepinephrine or its pharmaceutically acceptable salt, one or more sulfite antioxidants and an ion chelator. The present invention also provides an infusion container filled with an aqueous solution of norepinephrine or its pharmaceutically acceptable salt, wherein the said solution is stable for a prolonged period of time and can be terminally sterilized by autoclaving.
39 - Transport, packaging, storage and travel services
Goods & Services
Retail pharmacy services; mail order pharmacy services; pharmaceutical services, namely, processing telephone prescription orders in retail and central fill pharmacies Distribution services, namely, delivery of pharmaceutical products
39 - Transport, packaging, storage and travel services
Goods & Services
Retail pharmacy services; mail order pharmacy services; pharmaceutical services, namely, processing telephone prescription orders in retail and central fill pharmacies Distribution services, namely, delivery of pharmaceutical products
The present invention relates to a method of treating blepharitis comprising administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis. The active ingredient comprises a glucocorticoid in an ophthalmically acceptable vehicle, such as DuraSite® 2. Additionally, the present invention discloses a kit that includes: (a) a composition comprising about 0.1% by weight dexamethasone in an ophthalmically acceptable vehicle and, optionally, (b) instructions for using the composition for the treatment of blepharitis.
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61K 9/00 - Medicinal preparations characterised by special physical form
A parenteral dosage form of diltiazem, comprising a ready-to-infuse, stable aqueous solution comprising diltiazem or its pharmaceutically acceptable salt, a pharmaceutically acceptable stabilizer selected from cyclic oligosaccharides, and an infusion container fdled with the said aqueous solution.
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 9/00 - Medicinal preparations characterised by special physical form
A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or pharmaceutically acceptable salt thereof as a sole active ingredient, one or more pH adjusting agents, and optionally one or more co-solvents, wherein the pH of the aqueous solution is such that it contains substantially lower amount of impurity of Formula I and impurity of Formula II as compared to aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25° C. and 60% relative humidity for at least three months.
A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or pharmaceutically acceptable salt thereof as a sole active ingredient, one or more pH adjusting agents, and optionally one or more co-solvents, wherein the pH of the aqueous solution is such that it contains substantially lower amount of impurity of Formula I and impurity of Formula II as compared to aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25° C. and 60% relative humidity for at least three months.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the prevention of breast cancer in post-menopausal women; Pharmaceutical preparations for the treatment and prevention of bone/skeletal diseases
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the prevention of breast cancer in post-menopausal women; Pharmaceutical preparations for the treatment and prevention of bone/skeletal diseases
69.
METHODS FOR TREATMENT OF SUBJECTS WITH PLAQUE PSORIASIS OF THE SCALP
The disclosure relates to an anti-IL-23p19 antibody hum13B8-b or antigen binding fragment thereof and its use in the treatment of plaque psoriasis of the scalp.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The present invention discloses an extended release multi-particulate sprinkle composition comprising a plurality of discrete units, each discrete unit comprising quetiapine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Eye drops; Ocular pharmaceuticals; Pharmaceutical preparations for the treatment and prevention of diseases or disorders of the eye; Pharmaceutical preparations for the treatment of inflammation and pain in the eye
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Cardiovascular drugs for use for the prevention of stroke;
cardiovascular drugs for use in the treatment of congestive
heart failure; cardiovascular drugs for use in angina
pectoris; cardiovascular drugs for the treatment of
arrhythmias; cardiovascular drugs for use in myocardial
infarction.
75.
Method of Injecting Dihydroergotamine Into The Body
A method is provided for the acute treatment of migraine headaches with or without aura by injecting dihydroergotamine mesylate into a subject. The method includes storing the dihydroergotamine mesylate in an autoinjector at room temperature in a foil pouch. The method further includes removing the autoinjector from the pouch; removing a cap of the autoinjector; pushing the autoinjector down against an injection site of the subject to depress a safety guard; pressing and releasing an activation button on the autoinjector to start injection; and holding the autoinjector against the injection site for at least 10 seconds irrespective of whether a click is generated. The method further includes confirming that the injection is complete by viewing a change of color in a viewing window of the autoinjector, and lifting the autoinjector up away from the injection site and allowing the guard to drop down and lock over a needle.
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
76.
METHODS FOR TREATMENT OF SUBJECTS WITH PLAQUE PSORIASIS OF THE SCALP
The disclosure relates to an anti-IL-23p19 antibody hum13B8-b or antigen binding fragment thereof and its use in the treatment of plaque psoriasis of the scalp.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The present invention relates to long acting glucagon-like peptide-1 and human glucose-dependent insulinotropic polypeptide (GIP) agonist polypeptides which may be useful for treating type 2 diabetes mellitus (T2D), diabetes with obesity, obesity and hyperlipidemia.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
The present disclosure relates to a combination of the anti-IL-23 antibody tildrakizumab in combination with a corticosteroid for use in the treatment of plaque psoriasis.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
The present disclosure relates to a combination of the anti-IL-23 antibody tildrakizumab in combination with a corti¬ costeroid for use in the treatment of plaque psoriasis.
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
81.
EXTENDED RELEASE LIQUID COMPOSITIONS OF GUAIFENESIN
The present invention relates to extended release liquid compositions of guaifenesin. The extended release liquid compositions are in the form of suspensions which are ready-to-use or suspensions which are reconstituted from powder. It also relates to processes for the preparation of said extended release liquid compositions.
The present invention relates to tirzepatide or a pharmaceutically acceptable salt thereof. The present invention also relates to a process for the preparation of tirzepatide or pharmaceutically acceptable salt thereof. The present invention also relates to novel fragments as intermediates and use thereof in the preparation of tirzepatide.
C07C 233/47 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
C07K 1/04 - General processes for the preparation of peptides on carriers
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A perfusion container for directly administering to patients a dose of an antineoplastic drug calculated according to a patient's parameter, wherein the first perfusion container comprises a solution of antineoplastic drug at a concentration and volume such that the amount of antineoplastic drug in the container is equal to the calculated dose for one patient but less than the calculated dose for a second patient, the calculated dose is provided to first patient within 5% variance by directly administering the full volume of the solution of antineoplastic drug from the first perfusion container, further the first perfusion container is accompanied by a second top-up perfusion container comprising a solution of antineoplastic drug at a concentration and volume such that the calculated dose is provided within 5% variance by directly administering the full volume of the solution of antineoplastic drug from the first perfusion container and the second top-up container to the second patient.
A method is provided for the acute treatment of migraine headaches with or without aura by injecting dihydroergotamine mesylate into a subject. The method includes storing the dihydroergotamine mesylate in an autoinjector at room temperature in a foil pouch. The method further includes removing the autoinjector from the pouch; removing a cap of the autoinjector; pushing the autoinjector down against an injection site of the subject to depress a safety guard; pressing and releasing an activation button on the autoinjector to start injection; and holding the autoinjector against the injection site for at least 10 seconds irrespective of whether a click is generated. The method further includes confirming that the injection is complete by viewing a change of color in a viewing window of the autoinjector, and lifting the autoinjector up away from the injection site and allowing the guard to drop down and lock over a needle.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A parenteral dosage form having an infusion container filled with an aqueous solution in volumes ranging from 40 ml to 500 ml comprising 1 mg/ml to 2 mg/ml of carboplatin, wherein the solution contains known impurity of 1, 1-cyclobutanedicarboxylic acid in an amount of not more than 1.0% by weight of carboplatin and the solution remains physically stable when stored at room temperature.
A method of providing and/or injecting octreotide acetate to a subject in need thereof includes storing the octreotide acetate in a cartridge of a multi-use multi-dose injector provided with a variable dose setter and actuator. The injector includes a needle configured for subcutaneous administration of the octreotide acetate, the octreotide acetate having a concentration of 2,500 μg/mL. The method further includes permitting setting of a dose of the octreotide acetate by rotation of the variable dose setter. The injector is configured to provide at least one audible feedback during the rotation. The method further includes operating the actuator to deliver the octreotide acetate from the cartridge through the needle to treat the subject. The injector is provided with multiple surface portions.
The present invention relates to a method for enabling hospitals or clinics to administer a dose of a drug to patients in need thereof while avoiding steps of manipulation, dilution, reconstitution, dispensing, sterilization, transfer, handling or compounding before intravenous administration.
The present invention further relates to a perfusion system comprising different sets of perfusion containers, each container comprising a ready-to-infuse, stable, sterile, aqueous perfusion solution of a drug, wherein the set of perfusion containers alone or in combination provides for direct intravenous administration of a desired dose of the drug to a patient in need thereof, such that the delivered dose is equal to or within ±5% of the calculated dose.
A61K 9/00 - Medicinal preparations characterised by special physical form
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
B65B 55/04 - Sterilising wrappers or receptacles prior to, or during, packaging
B65D 81/26 - Adaptations for preventing deterioration or decay of contentsApplications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, fluids, e.g. exuded by contentsApplications of corrosion inhibitors or desiccators
A61M 5/14 - Infusion devices, e.g. infusing by gravityBlood infusionAccessories therefor
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
G16Z 99/00 - Subject matter not provided for in other main groups of this subclass
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
Provided herein are formulations for topical ophthalmic formulations containing 0.087-0.093 wt % of cyclosporine, and methods of making and using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and/or a polyalkoxylated alcohol and may include nanomicelles. Also included herein are methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A stable nanomicellar ophthalmic solution comprising cyclosporine and a method of preparing the nanomicellar solution. The present invention further relates to a stable nanomicellar solution comprising a cyclosporine form with characteristic XRD peaks at 2-theta (deg.) 6.9, 7.8, 9.4 and 15.9 or amorphous cyclosporine. The present invention also relates to use of this stable nanomicellar ophthalmic solution in the treatment of dry eye.
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
The present invention relates to an extended release multiparticulate composition comprising a plurality of discrete units, each discrete unit comprising ranolazine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The said multiparticulate composition is sprinkled onto soft foods or liquids for oral administration. Further, the multiparticulate composition is bioequivalent to the marketed extended release tablet. It further relates to a process of preparation of said multiparticulate composition and method of treatment of patients suffering from angina by administering said composition.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of neurologic disorders, disorders of the nervous system, mental illness, major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, chronic musculoskeletal pain
The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.
A method of preparing patients for cataract surgery includes topical administration of a cyclosporine solution. The administration may occur twice daily and may occur over the course of 28 days. The method results in an improved error prediction for 1-month spherical equivalent refractive outcome and improved ocular surface irregularity.
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for the treatment of vertigo; Medicinal preparations and substances for the treatment of vertigo; anti-vertigo medicines.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Intestinal disorder medicine for the treatment of ulcerative colitis; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of dermatitis, eczema and psoriasis; pharmaceutical preparations for the treatment of digestive diseases and disorders, namely, crohn's disease, irritable bowel syndrome; pharmaceutical preparations for the treatment of immunologic diseases and disorders namely, autoimmune diseases and disorders; pharmaceutical preparations for the treatment of respiratory and pulmonary diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Intestinal disorder medicine for the treatment of ulcerative colitis; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of dermatitis, eczema and psoriasis; pharmaceutical preparations for the treatment of digestive diseases and disorders, namely, crohn's disease, irritable bowel syndrome; pharmaceutical preparations for the treatment of immunologic diseases and disorders namely, autoimmune diseases and disorders; pharmaceutical preparations for the treatment of respiratory and pulmonary diseases and disorders
